Results 1 to 10 of about 192,309 (409)

Warfarin use and vestibular dysfunction insights from NHANES data, network pharmacology, Mendelian randomization, and molecular docking [PDF]

Scientific Reports
Despite numerous anticoagulants available, warfarin is widely used due to its efficacy and cost-effectiveness in treating thromboembolic diseases. However, its potential impact on vestibular function remains unexplored.
Shihan Liu, Lingli Zhang, Wenlong Luo
doaj   +2 more sources

Number needed to treat for net clinical benefit of oral anticoagulants in Asian patients with atrial fibrillation [PDF]

Journal of Arrhythmia
Background Oral anticoagulants (OAC) can reduce ischemic stroke/systemic embolism (SSE) in patients with non‐valvular atrial fibrillation (AF) while increasing the risk of major bleeding. We aimed to analyze the number needed to treat for the net benefit
Rungroj Krittayaphong, Satchana Pumprueg, Ahthit Yindeengam, Gregory Y. H. Lip   +3 more
doaj   +2 more sources

Optimizing Warfarin Dosing using Deep Reinforcement Learning [PDF]

Journal of Biomedical Informatics, 137 (2023) 104267, 2022
Warfarin is a widely used anticoagulant, and has a narrow therapeutic range. Dosing of warfarin should be individualized, since slight overdosing or underdosing can have catastrophic or even fatal consequences. Despite much research on warfarin dosing, current dosing protocols do not live up to expectations, especially for patients sensitive to ...
arxiv   +1 more source

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Circulation, 2022
Supplemental Digital Content is available in the text. Background: Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke prevention in atrial fibrillation.
A. Carnicelli, H. Hong, S. Connolly, J. Eikelboom, R. Giugliano, D. Morrow, M. Patel, L. Wallentin, J. Alexander, M. Bahit, A. Benz, E. Bohula, T. Chao, L. Dyal, M. Ezekowitz, K. Fox, B. Gencer, J. Halperin, Z. Hijazi, S. Hohnloser, Kaiyuan Hua, E. Hylek, Eri Toda Kato, J. Kuder, R. Lopes, K. Mahaffey, J. Oldgren, J. Piccini, C. Ruff, J. Steffel, D. Wojdyla, C. Granger   +31 more
semanticscholar   +1 more source

A Case Of Late-onset Warfarin Induced Skin Necrosis Resulting In Mortality

Hitit Medical Journal, 2023
Warfarin-induced skin necrosis is a rare complication of warfarin therapy and is associated with high mortality. Here, we present a case of warfarin-induced skin necrosis, that was fatal in a 53-year-old female patient who was started on warfarin ...
Pınar Korkmaz, Sinem Bayrakçı
doaj   +1 more source

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

New England Journal of Medicine, 2011
BACKGROUND The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment.
S. Pearson, R. Troughton, A. Richards
semanticscholar   +2 more sources

Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial

Blood Advances, 2021
Key Points The primary outcome, stroke, occurred in 6 of 23 patients randomized to apixaban compared with 0 of 25 patients randomized to warfarin. This study with limitations suggests that apixaban is not an equitable substitute for warfarin to prevent ...
S. Woller, S. Stevens, David A Kaplan, Tzu‐Fei Wang, D. Branch, Danielle Groat, E. Wilson, Brent P. Armbruster, V. Aston, J. Lloyd, M. Rondina, C. Elliott   +11 more
semanticscholar   +1 more source

Dabigatran versus warfarin in patients with atrial fibrillation.

New England Journal of Medicine, 2009
BACKGROUND Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.
S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P. Reilly, E. Themeles, Jeanne Varrone, Susan Wang, M. Alings, D. Xavier, Jun Zhu, R. Diaz, B. Lewis, H. Darius, H. Diener, C. Joyner, L. Wallentin   +19 more
semanticscholar   +1 more source

Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi.

JAMA cardiology, 2020
Importance Left ventricular (LV) thrombi can arise in patients with ischemic and nonischemic cardiomyopathies. Anticoagulation is thought to reduce the risk of stroke or systemic embolism (SSE), but there are no high-quality data on the effectiveness of ...
A. Robinson, C. Trankle, G. Eubanks, C. Schumann, P. Thompson, Ryan Wallace, S. Gottiparthi, Benjamin K Ruth, C. Kramer, M. Salerno, K. Bilchick, C. Deen, M. Kontos, J. Dent   +13 more
semanticscholar   +1 more source

Thromboembolic and neurologic sequelae of discontinuation of an antihyperlipidemic drug during ongoing warfarin therapy [PDF]

, 2017
Warfarin and antihyperlipidemics are commonly co-prescribed. Some antihyperlipidemics may inhibit warfarin deactivation via the hepatic cytochrome P450 system.
Bilker, Warren B., Brensinger, Colleen M., Hennessy, Sean, Kimmel, Stephen E., Leonard, Charles E., Whitaker, Heather J.   +5 more
core   +2 more sources